Our study validates the feasibility of predicting HER2 overexpression in prostate cancer using radiomic features derived from bp-MRI, supporting the broader potential of imaging-based molecular phenotyping in oncology. This evidence concerns the gene ERBB2 and Familial prostate cancer.